Investor Omega Fund VI, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Omega Fund VI, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-02-14 13G/A LXEO / Lexeo Therapeutics, Inc. 2,157,623 1,184,636
2024-02-14 13G/A IKNA / Ikena Oncology, Inc. 2,249,123 2,249,123
2024-02-14 13G LXEO / Lexeo Therapeutics, Inc. 2,157,623
2024-02-14 13G/A ALPN / Alpine Immune Sciences, Inc. 2,415,050 0
2023-02-13 13G/A ALPN / Alpine Immune Sciences, Inc. 2,415,050 2,415,050
2022-02-14 13G/A ALPN / Alpine Immune Sciences, Inc. 2,415,050
2022-02-14 13G IKNA / Ikena Oncology, Inc. 2,249,123
2022-02-14 13G IMGO / Imago BioSciences Inc 3,018,737
2021-02-12 13G CMPI / Checkmate Pharmaceuticals Inc 1,335,050
2021-02-12 13G SPRB / Spruce Biosciences, Inc. 2,161,023